FDA Approves Third Drug in BD Simplist Prefilled Injectable Line of Products

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) BDX, announced today that the U.S. Food and Drug Administration (FDA) has approved the third drug to be offered in the new BD Simplist™ line of ready-to-administer prefilled generic injectables. The third BD Simplist product to launch is Ondansetron Injection, USP 4mg/2mL (2mg/mL), an injectable antiemetic. Ondansetron Injection, USP which is used to prevent postoperative nausea and vomiting, is currently on the FDA drug shortage list due to recent demand increases and supply issues faced by other manufacturers.1,2 Ondansetron Injection, USP also can be used with initial and repeat courses of emetogenic cancer chemotherapy. "We're proud to be expanding our BD Simplist products with a drug like Ondansetron Injection, USP which is in high demand among clinicians and fills a need for an intervention that can be administered quickly," said Mark Sebree, President, BD Rx. "As we establish our product line with a third drug approval, we are seeing even further indication of the positive response to our new BD Simplist prefilled injectables especially among repeat customers." In March, BD announced that See full press release